Nikolay Conev

Researcher Next ID · RN-016793

Researcher · Medicine

, Bulgaria

Not currently recruitingFunding unknown

Research interests

Medicine

Biochemistry, Genetics and Molecular Biology

Lung Cancer Research Studies

Neuroendocrine Tumor Research Advances

Peptidase Inhibition and Analysis

MicroRNA in disease regulation

Circular RNAs in diseases

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
ESMO Open · 2022 · 10.1016/j.esmoop.2022.100408
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30539-8
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30539-8
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
The Lancet · 2019 · 10.1016/s0140-6736(19)32222-6
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
The Lancet · 2019 · 10.1016/s0140-6736(19)32222-6

No projects listed.